title: Effect of Angiotensin-(1-7) on Aortic Response, TNF-α, IL-1β and Receptor for Advanced Glycation Endproduct in Rat's Adjuvant-Induced Arthritis.
abstract: Altered vascular reactivity due to endothelial dysfunction, consequent to vascular damage, is observed in rheumatoid arthritis. We investigated the effect of angiotensin (Ang)-(1-7) on vasculature changes in arthritis induced by complete Freund's adjuvant in male Wistar rats. Arthritis decreased soluble receptor for advanced glycation end products (sRAGE) whereas elevated aortic RAGE expression, increased interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), systolic blood pressure and the contractility induced by phenylephrine and KCl. Moreover, arthritis decreased the relaxing effect of acetylcholine. Neither arthritis nor Ang-(1-7) altered sodium nitroprusside relaxation. Ang-(1-7) reversed the effect of arthritis on TNF-α, sRAGE and RAGE expression without any effect on the IL-1β. Ang-(1-7) decreased phenylephrine and KCl contractility, especially in the endothelial-denuded aorta, whereas increased acetylcholine relaxation in the endothelial-intact aorta. Ang-(1-7) could find its place in the treatment protocol of arthritis and vascular diseases.
authors: Department of Medical Pharmacology, Faculty of Medicine, Pamukkale University, Denizli, Turkey.
authors: Öznur
authors: Ö
authors: Açikalin
authors: Funda F
authors: FF
authors: Bölükbaşi Hatip
authors: Ruyal F
authors: RF
authors: Tan
authors: Izzettin
authors: I
authors: Hatip-Al-Khatib
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000803:Angiotensin I / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D001169:Arthritis, Experimental / Q000097:blood / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D053583:Interleukin-1beta / Q000097:blood*; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use; D010656:Phenylephrine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D000067759:Receptor for Advanced Glycation End Products / Q000097:blood / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D053583:Interleukin-1beta; D010446:Peptide Fragments; D000067759:Receptor for Advanced Glycation End Products; D014409:Tumor Necrosis Factor-alpha; D010656:Phenylephrine; D011189:Potassium Chloride; D000803:Angiotensin I; C118790:angiotensin I (1-7); D000109:Acetylcholine